Gliknik
Latest round
- Series C
Last raised
- Jun 2021
Total raised
- $21M
Investors
- 4
About Gliknik
Gliknik Inc.Founded in 2007 and headquartered in Baltimore, US, Gliknik Inc. specializes in developing biologics for immune disorders.38 mn.Gliknik Inc. specializes in the discovery and development of innovative biologics aimed at treating immune disorders, particularly autoimmune diseases and certain cancers. The company’s core product offerings include GL-2045 and GL-0719, both of which are recombinant Fc fusion proteins currently in clinical trials. GL-2045 is designed to mimic the effects of intravenous immunoglobulin (IVIG) in treating autoimmune diseases, which is approved for various conditions and has a significant market presence, generating approximately USD 12 bn annually. GL-0719 selectively inhibits the classical and lectin complement pathways to treat autoimmune diseases associated with their over-activation. Together, these products target a wide range of end-users, including patients suffering from conditions like chronic inflammatory demyelinating polyneuropathy (CIDP) and other autoimmune diseases.Gliknik’s revenue model is anchored in the successful progression of its clinical assets, particularly GL-2045 and GL-0719. As these biologics advance through clinical trials, Gliknik could enter into partnerships with larger pharmaceutical companies for development and distribution, significantly affecting its revenue streams.In June 2023, Gliknik Inc. The company plans to continue the clinical trials for GL-2045 and GL-0719, with expectations for potential market release following successful trials. Additionally, Gliknik aims to expand its market presence in Europe and North America, targeting new partnerships with pharmaceutical companies by the end of 2024 to enhance its distribution and commercialization capabilities.
Who invested in Gliknik
4 investors across 3 rounds
See all investors in Gliknik
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Gliknik
Who invested in Gliknik?
Gliknik has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Gliknik raised?
Gliknik has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Gliknik last raise money?
Gliknik's most recent round on record is a Series C, in Jun 2021.
What does Gliknik do?
Gliknik is a biotechnology company.
Where is Gliknik headquartered?
Gliknik is headquartered in Baltimore, US.
Which VCs invest in companies like Gliknik?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Gliknik's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Gliknik? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.